Combined Analysis of SNP Array Data Identifies Novel CNV Candidates and Pathways in Ependymoma and Mesothelioma

Gabriel Wajnberg1, Benilton S Carvalho2, Carlos G Ferreira3

  • 1Bioinformatics Unit, Clinical Research Coordination, National Cancer Institute of Brazil (INCA), 20231-050 Rio de Janeiro, RJ, Brazil ; Graduate Program in Systems and Computational Biology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), 21040-360 Rio de Janeiro, RJ, Brazil ; Laboratory of Functional Genomics and Bioinformatics, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), 21040-360 Rio de Janeiro, RJ, Brazil.

Insights

This study introduces an innovative open-source strategy to detect copy number variations and cancer-associated pathways. The method identified novel variations linked to chemotherapy resistance and specific disease pathways.

Area of Science:

  • Genomics
  • Bioinformatics
  • Cancer Research

Background:

  • Copy number variation (CNV) is a key genomic alteration in cancer.
  • Existing methods often rely on proprietary software, limiting accessibility.
  • Identifying CNVs and associated pathways is crucial for understanding cancer.

Purpose of the Study:

  • To develop and validate an innovative strategy for identifying novel CNVs and cancer-associated pathways.
  • To utilize open-source software for improved accessibility and reproducibility.
  • To assess the tool's efficacy using mesothelioma and ependymoma datasets.

Main Methods:

  • Combined two open-source bioinformatics packages for CNV detection.
  • Applied the strategy to published mesothelioma and ependymoma genomic datasets.
  • Analyzed identified CNVs for associations with cancer chemotherapy resistance and altered pathways.

Main Results:

  • Successfully detected known and novel CNVs associated with cancer chemotherapy resistance.
  • Identified specific altered pathways, including cell adhesion in mesothelioma and glutamatergic synapse regulation in ependymoma.
  • Demonstrated the utility of the open-source strategy in analyzing complex cancer genomics data.

Conclusions:

  • Presents a novel, accessible strategy for CNV and pathway analysis in cancer using open-source tools.
  • Highlights the potential for discovering novel cancer-related genomic alterations and pathways.
  • Provides a valuable tool for cancer genomics research and drug discovery.

Related Concept Videos

Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
19.3K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.9K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.7K